logo

For the Inventor, By the Inventor

Munich, Germany

Micromet Ag


USPTO Granted Patents = 25

% Expired Patents = 24.0


Trademarks = 1

Forward Citations = 993

Loading Chart...
Loading Chart...

66 inventors (with patents filed for the assignee):

goldMedal Peter Kufer (13 out of 65 patents)

silverMedal Tobias Raum (9 out of 60 patents)

bronzeMedal Ralf Lutterbüse (6 out of 26 patents)

4.  Patrick A Baeuerle (5 out of 35 patents)

5.  Birgit Kohleisen (4 out of 7 patents)

6.  Andreas Wolf (3 out of 16 patents)

7.  Ulla Lenkkeri-Schütz (3 out of 5 patents)

8.  Patrick Bäuerle (3 out of 7 patents)

9.  Doris Rau (2 out of 27 patents)

10.  Steven Zeman (2 out of 5 patents)

11.  Christian Itin (2 out of 5 patents)

12.  Meera Berry (2 out of 4 patents)

13.  Bernd Dorken (2 out of 2 patents)

14.  Gert Riethmuller (2 out of 2 patents)

15.  Ralf Bargou (2 out of 2 patents)


Core Competencies:
CD19XCD3
Pharmaceutical Compositions
Antibody Fragments
Deimmunized Molecules
T Cell Modulators
Tumor Treatment
B-Cell Disorders
Human Antibodies
Binding Site Domains
mRNA Amplification
Recombinant Polypeptides
Cancer Therapy

25 patents:

1. 8840888 - Dosage regimen for administering a CD19XCD3 bispecific antibody (2014-09-23),
2. 8394926 - Pharmaceutical compositions with resistance to soluble CEA (2013-03-12),
3. 8247194 - Preparation of scFv antibody fragments (2012-08-21),
4. 8236308 - Composition comprising cross-species-specific antibodies and uses thereof (2012-08-07),
5. 8101722 - Less immunogenic binding molecules (2012-01-24),
6. 8076459 - Multispecfic deimmunized CD3-binders (2011-12-13),
7. 8017748 - Antibody neutralizers of human granulocyte macrophage colony stimulating factor (2011-09-13),
8. 8007796 - Means and methods for the treatment of tumorous diseases (2011-08-30),
9. 7976842 - Treatment of metastatic breast cancer (2011-07-12),
10. 7964707 - Anti-IL2 antibodies (2011-06-21),
11. 7919089 - Pharmaceutical composition comprising a bispecific antibody for EpCAM (2011-04-05),
12. 7820166 - Potent T cell modulating molecules (2010-10-26),
13. 7635472 - Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders (2009-12-22),
14. 7632925 - Antibodies that bind human 17-A1/EpCAM tumor antigen (2009-12-15),
15. 7575923 - CD19xCD3 specific polypeptides and uses thereof (2009-08-18),
Company Overview
Micromet AG, based in Munich, specializes in the development of innovative biopharmaceuticals, particularly in the field of immunotherapy. The company focuses on harnessing the power of the immune system to create targeted treatments for cancer and other serious diseases. With a strong emphasis on research and development, Micromet AG is dedicated to advancing therapeutic solutions that improve patient outcomes and address unmet medical needs, positioning itself as a key player in the biopharmaceutical landscape.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

25 Patents

#113 in W-8000 Munich

#1,846 in Germany

#25,710 in the World

Munich, DE
Munich, Germany

Micromet Ag

Forward Citations = 993

66 inventors:

goldMedal Peter Kufer (13 out of 65 patents)

silverMedal Tobias Raum (9 out of 60 patents)

bronzeMedal Ralf Lutterbüse (6 out of 26 patents)

4.  Patrick A Baeuerle (5 out of 35 patents)

5.  Birgit Kohleisen (4 out of 7 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Micromet Ag. Retrieved from https://idiyas.com/company/micromet-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…